Company: VMCWF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001827
Chunk: 281

Company: Valuence Merger Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 281
---
 Robinson Humphrey, where he advised many publicly traded industrial companies
on M&A and capital market transactions. Before joining SunTrust, Mr. Lee was at Progress Partners, a media and technology-focused
investment banking firm, where he executed M&A and financing projects for early-to-mid-stage clients and managed three investment
funds at Progress Ventures, its affiliated venture capital arm. Mr. Lee received his B.A. from Hanyang University and M.B.A. from Cornell
University.

Dr.
Gene Young Cho has been our Chief Operating Officer since our inception. Dr. Gene Young Cho brings leadership and experience
in business operations and life sciences. Currently, he is the Executive Director of CG Pharmaceuticals, Inc., the U.S. subsidiary of
CrystalGenomics. In this role, Dr. Cho is focused on developing growth strategies as well as providing strategic planning and management
of the operations and expansion of CG Pharmaceuticals. Previously, Dr. Cho worked as a life sciences consultant at L.E.K. Consulting,
working with clients in biopharmaceuticals, contract services, medical devices, healthcare services, HCIT, digital health, and AI. Some
of his specific experiences include working on large-scale M&A transactions of leading biopharmaceuticals or healthcare service companies,
supporting target identification for acquisition, implementing pipeline development strategies, and optimizing governance structures
of fast-growing biotech companies. He also brings strong experience in the Asian markets through his professional network focused around
supporting emerging technologies and startups. Dr. Cho received his B.S. in bioengineering at U.C. Berkeley, Ph.D. from the NYU School
of Medicine in biomedical imaging and completed his post-doc at Memorial Sloan Kettering focusing on breast cancer imaging. Dr. Cho is
also the author of over 10 publications in journals and several conference abstracts during his time as a researcher. He is the son of
our director nominee, Dr. Joong Myung Cho.

Dr.
Joong Myung Cho, has been one of our directors since March 2022, is the Founder, Chairman and Chief Executive Officer of CrystalGenomics
and has over 35 years of experience in the biopharmaceuticals industry from R&D to commercialization of novel drugs and is a global
leading life sciences expert. Dr. Cho has previously served as the Executive Senior Vice President and Director of R&D Biotech Research
Institute at LG Life Sciences (formerly LG Chem). During his tenure, the biopharmaceutical institute at LG became